Market Research Reports and Industry Reports

Parkinsons Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Description
 
Parkinson’s Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson’s Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer’s disease it is the second most common neurodegenerative disease worldwide.
 
 Parkinson’s Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient’s quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson’s Disease (PD) include tremors and difficulty walking. Parkinson’s Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell.
 
 There are several different drug classes available to relieve Parkinson’s Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson’s Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as off- time), which causes symptoms to return before the next dose.
 
 With the current marketed drugs focusing primarily on symptomatic relief, Parkinson’s Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.
 
 Scope
 
 A brief introduction to Parkinson’s Disease (PD), including pathogenesis, disease staging, diagnosis and treatment algorithms
 
 Comprehensive analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
 
 Comprehensive analysis of the pipeline for Parkinson’s Disease (PD) therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of Phase distribution, molecule type and molecular target
 
 Additional thorough analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate for each molecule type and mechanism of action
 
 Multi-scenario market forecast data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
 
 Discussion of the drivers of and barriers to market growth
 
 Discussion of the licensing and co-development deals landscape in Parkinson’s Disease (PD), by stage of development, molecule type and mechanism of action, as well as analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals
 
 Reasons To Buy
 
 Understand the different levels of Parkinson’s Disease (PD) therapy from early-stage to advanced
 
 Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
 
 Observe the trends in clinical trial duration and size among clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or forthcoming developmental programs for Parkinson’s Disease (PD) therapeutics
 
 Observe the trends in clinical trial duration and size among clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for Parkinson’s Disease (PD) therapeutics
 
 Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the Parkinson’s Disease (PD) therapeutics market

 2 Introduction 9
 
 2.1 Disease Introduction 9
 
 2.2 Symptoms 9
 
 2.3 Etiology 10
 
 2.3.1 Genetic Factors 10
 
 2.3.2 Environmental Factors 11
 
 2.3.3 Aging 11
 
 2.4 Pathophysiology 12
 
 2.5 Epidemiology 13
 
 2.6 Disease Stages 14
 
 2.7 Co-morbidities and Complications 15
 
 2.8 Diagnosis 15
 
 2.9 Assessment of Disease Severity 16
 
 2.9.1 Hoehn and Yahr scale 16
 
 2.9.2 Unified Parkinson’s Disease Rating Scale 16
 
 2.10 Treatment 18
 
 2.10.1 Pharmacological Therapies 18
 
 2.10.2 Non-pharmacological Treatments 20
 
 2.11 Treatment Algorithm 21
 
 2.11.1 Early Parkinson’s Disease 21
 
 2.11.2 Advanced Parkinson’s Disease 23
 
 3 Marketed Products 26
 
 3.1 Overview 26
 
 3.1.1 Dopamine Replacement Therapies 26
 
 3.1.2 MAO-B Inhibitors 29
 
 3.1.3 Dopamine Agonists 31
 
 3.1.4 COMT Inhibitors 37
 
 3.1.5 Other Drugs Targeting Non-motor Symptoms of PD 40
 
 3.2 Comparative Efficacy and Safety 41
 
 4 Pipeline for Parkinson’s Disease 45
 
 4.1 Overview 45
 
 4.2 Pipeline Distribution by Mechanism of Action/Molecular Target 47
 
 4.3 Clinical Trials 50
 
 4.3.1 Failure Rate 50
 
 4.3.2 Clinical Trial Duration 52
 
 4.3.3 Clinical Trial Size 54
 
 4.3.4 Comparison of Average Trial Metrics by Phase and Mechanism of Action 56
 
 4.4 Promising Pipeline Molecules 57
 
 4.4.1 Opicapone – Bial 57
 
 4.4.2 Nuplazid (pimavanserin) – Acadia Pharmaceuticals 59
 
 4.4.3 Nurelin (Amantadine Hydrochloride Extended-Release) – Adamas Pharmaceuticals 60
 
 4.4.4 Tozadenant – Biotie Therapies 61
 
 4.4.5 APL-130277 (apomorphine hydrochloride) – Cynapsus Therapeutics 62
 
 4.4.6 P2B001 (pramipexole dihydrochloride + rasagiline mesylate) – Pharma Two B 64
 
 4.4.7 DM-1992 (levodopa + carbidopa extended release) – Depomed 64
 
 4.4.8 CVT-301 (levodopa) – Acorda Therapeutics 66
 
 4.4.9 Dipraglurant Immediate-Release– Addex Therapeutics 66
 
 4.4.10 Accordion Pill (levodopa and carbidopa) – Intec Pharma 67
 
 4.4.11 ND-0612L (levodopa and carbidopa) – NeuroDerm 68
 
 4.5 Heatmaps of Safety and Efficacy for Parkinson’s Disease Pipeline and Marketed Products 70
 
 4.6 Pipeline Product Heat Map and Product Competitiveness Framework 74
 
 5 Market Forecast to 2021 75
 
 5.1 Geographical Markets 75
 
 5.1.1 Global Market 75
 
 5.1.2 North America 77
 
 5.1.3 Top Five European Markets 80
 
 5.1.4 Japan 85
 
 5.2 Drivers and Barriers 86
 
 5.2.1 Drivers 86
 
 5.2.2 Barriers 87
 
 6 Strategic Consolidations 89
 
 6.1 Major Co-Development Deals 89
 
 6.1.1 TechnoPhage Enters into Co-Development Agreement with University of Macau 91
 
 6.1.2 Dainippon Sumitomo Pharma Enters into Research Agreement with CiRA and Hitachi 91
 
 6.1.3 MJFF Enters into Agreement with Prothena 91
 
 6.1.4 Ubiquigent Enters into Co-Development Agreement with UbiQ 92
 
 6.1.5 23andMe Partners with Genentech 92
 
 6.2 Major Licensing Deals 92
 
 6.2.1 Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine 95
 
 6.2.2 Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 95
 
 6.2.3 Neuropore Therapies Enters into Licensing Agreement with UCB 95
 
 6.2.4 Catalent Pharma Solutions Enters into Licensing Agreement with Sellas Life Sciences 95
 
 6.2.5 MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer 96
 
 7 Appendix 97
 
 7.1 All Pipeline Drugs by Stage of Development 97
 
 7.1.1 Discovery 97
 
 7.1.2 Preclinical 101
 
 7.1.3 IND/CTA-filed 113
 
 7.1.4 Phase I 114
 
 7.1.5 Phase II 116
 
 7.1.6 Phase III 118
 
 7.1.7 Pre-registration 119
 
 7.2 Market Forecasts to 2021 119
 
 7.2.1 Global 119
 
 7.2.2 US 119
 
 7.2.3 Canada 120
 
 7.2.4 UK 120
 
 7.2.5 France 120
 
 7.2.6 Germany 121
 
 7.2.7 Italy 121
 
 7.2.8 Spain 121
 
 7.2.9 Japan 122
 
 7.3 References 122
 
 7.4 Abbreviations 131
 
 7.5 Research Methodology 133
 
 7.6 Secondary Research 134
 
 7.7 Marketed Product Profiles 134
 
 7.8 Late-Stage Pipeline Candidates 134
 
 7.9 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 135
 
 7.10 Product Competitiveness Framework 135
 
 7.11 Pipeline Analysis 135
 
 7.11.1 Overall Pipeline 135
 
 7.11.2 Clinical Trials 135
 
 7.11.3 Failure Rate 135
 
 7.11.4 Clinical Trial Size 136
 
 7.11.5 Clinical Trial Duration 136
 
 7.11.6 Forecasting Model 136
 
 7.12 Deals Data Analysis 137
 
 7.13 Expert Panel Validation 137
 
 7.14 Contact Us 137
 
 7.15 Disclaimer 137


List Of Tables

 Table 1: Gene Mutations Related to Parkinson’s Disease and Corresponding Clinical Phenotypes 12
 
 Table 2: Hoehn and Yahr Scale and the Definition of Disability Stages 16
 
 Table 3: Unified Parkinson’s Disease Rating Scale 17
 
 Table 4: All Pipeline Products by Phase, Discovery 97
 
 Table 5: All Pipeline Products by Phase, Preclinical 101
 
 Table 6: All Pipeline Products by Phase, IND/CTA-filed 113
 
 Table 7: All Pipeline Products by Phase, Phase I 114
 
 Table 8: All Pipeline Products by Phase, Phase II 116
 
 Table 9: All Pipeline Products by Phase, Phase III 118
 
 Table 10: All Pipeline Products by Phase, Phase III and Pre-registration 119
 
 Table 11: Global, Parkinsons Disease Market Forecast, 2014–2021 119
 
 Table 12: US, Parkinsons Disease Market Forecast, 2014–2021 119
 
 Table 13: Canada, Parkinsons Disease Market Forecast, 2014–2021 120
 
 Table 14: UK, Parkinsons Disease Market Forecast, 2014–2021 120
 
 Table 15: France, Parkinsons Disease Market Forecast, 2014–2021 120
 
 Table 16: Germany, Parkinsons Disease Market Forecast, 2014–2021 121
 
 Table 17: Italy, Parkinsons Disease Market Forecast, 2014–2021 121
 
 Table 18 : Spain, Parkinsons Disease Market Forecast, 2014–2021 121
 
 Table 19: Japan, Parkinsons Disease Market Forecast, 2014–2021 122


List Of Figures

 Figure 1: Overview of the Basal Ganglia in the Normal State and Parkinson’s Disease State 13
 
 Figure 2: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products (Part 1) 42
 
 Figure 3: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products (Part 2) 43
 
 Figure 4: Pipeline for Parkinson’s Disease, Global, 2015 46
 
 Figure 5: Pipeline for Parkinson’s Disease by Molecular Target, Global, 2015 47
 
 Figure 6: Pipeline for Parkinson’s Disease by Mechanism of Action, Global, 2015 48
 
 Figure 7: Parkinson’s Disease, Global, Average Clinical Trial Failure Rate (%), 2006–2015 50
 
 Figure 8 : Parkinson’s Disease, Global, Clinical Trial Failure Rates for Small Molecules (%), 2006–2015 51
 
 Figure 9: Parkinson’s Disease, Global, Clinical Trial Failure Rates by Mechanism of Action (%), 2006–2015 52
 
 Figure 10: Parkinson’s Disease, Global, Clinical Trial Duration by Molecule Type, 2006–2015 53
 
 Figure 11: Parkinson’s Disease, Global, Clinical Trial Duration by Mechanism of Action, 2006–2015 54
 
 Figure 12: Parkinson’s Disease, Global, Clinical Trial Size by Molecule Type, 2006–2015 55
 
 Figure 13: Parkinson’s Disease, Global, Clinical Trial Size by Mechanism of Action, 2006–2015 56
 
 Figure 14: Pipeline for Parkinson’s Disease, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action, 2006–2015 57
 
 Figure 15: Parkinson’s Disease Market, Global, Annual Sales of Opicapone ($m), 2015–2021 58
 
 Figure 16: Parkinson’s Disease Market, Global, Annual Sales of Nuplazid ($m), 2016–2021 60
 
 Figure 17 : Parkinson’s Disease Market, Global, Annual Sales of Nurelin ($m), 2016–2021 61
 
 Figure 18: Parkinson’s Disease Market, Global, Annual Sales of Tozadenant ($m), 2018–2021 62
 
 Figure 19: Parkinson’s Disease Market, Global, Annual Sales of APL-130277 ($m), 2017–2021 63
 
 Figure 20: Parkinson’s Disease Market, Global, Annual Sales of P2B001 ($m), 2016–2021 64
 
 Figure 21: Parkinson’s Disease Market, Global, Annual Sales of DM-1992 ($m), 2018–2021 65
 
 Figure 22: Parkinson’s Disease Market, Global, Annual Sales of CVT-301 ($m), 2016–2021 66
 
 Figure 23: Parkinson’s Disease Market, Global, Annual Sales of Dipraglurant IR ($m), 2019–2021 67
 
 Figure 24: Parkinson’s Disease Market, Global, Annual Sales of the Accordion Pill ($m) 2018–2021 68
 
 Figure 25: Parkinson’s Disease Market, Global, Annual Sales of ND-0612L ($m) 2019–2021 69
 
 Figure 26: Parkinson’s Disease Market, Global, Efficacy Heat Map for Pipeline Products 71
 
 Figure 27: Parkinson’s Disease Market, Global, Efficacy Heat Map for Pipeline Products 71
 
 Figure 28: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products 72
 
 Figure 29: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products 73
 
 Figure 30: Parkinson’s Disease Market, Global, Product Competitiveness Early Parkinson’s Disease 74
 
 Figure 31: Parkinson’s Disease Market, Global, Product Competitiveness Advanced Parkinson’s Disease 74
 
 Figure 32: Parkinson’s Disease Market, Global, Treatment Patterns by Number of Patients (‘000), 2014–2021 76
 
 Figure 33: Parkinson’s Disease Market, Global, Market Size ($m), 2014–2021 76
 
 Figure 34: Parkinson’s Disease Market, US and Canada, Treatment Patterns by Number of Patients (‘000), 2014–2021 77
 
 Figure 35: Parkinson’s Disease Market, US and Canada, Annual Cost of Therapy ($), 2014–2021 79
 
 Figure 36: Parkinson’s Disease Market, US and Canada, Market Size ($), 2014–2021 80
 
 Figure 37: Parkinson’s Disease Market, Top Five EU Countries, Treatment Patterns by Number of Patients (‘000), 2014–2021 81
 
 Figure 38: Parkinson’s Disease Market, Tope Five EU Countries, Annual Cost of Therapy ($m), 2014–2021 83
 
 Figure 39: Parkinson’s Disease Market, Top Five EU Countries, Market Size ($m), 2014–2021 84
 
 Figure 40: Parkinson’s Disease Market, Japan, Treatment Patterns by Number of Patients (‘000) and the Annual Cost of Therapy ($), 2014–2021 85
 
 Figure 41: Parkinson’s Disease Market, Japan, Market Size ($m), 2014–2021 86
 
 Figure 42: Parkinson’s Disease Market, Global, Co-development Deals, 2006–2015 89
 
 Figure 43: Parkinson’s Disease Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006–2015 90
 
 Figure 44: Parkinson’s Disease Market, Global, Co-development Deals by Mechanism of Action, 2006–2015 91
 
 Figure 45: Parkinson’s Disease Market, Global, Licensing Deals, 2006–2015 93
 
 Figure 46: Parkinson’s Disease Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2015 94
 
 Figure 47: Parkinson’s Disease Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2015 94


Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

Description   Parkinson’s Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the

USD 4995View Report

Neuromodulation Market by Technology (Deep Brain Stimulation, Spinal Cord Stimulation, Transcranial Magnetic Stimulation) & by Application (Depression, Parkinson’s, Tinnitus, Alzheimer’s, Epilepsy, Ischemia, Obesity) - Trends & Global Forecast to 2020

Over the years, the global healthcare industry has witnessed a paradigm shift, and is now increasingly focused on minimally invasive therapies that not only treats a wide range of chronic

USD 4650View Report

Internal Neurostimulation Market, by Type (Spinal Cord Stimulation, Deep brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), by Application (Parkinson’s Disease, Chronic Pain), by Geography – Analysis & Forecasts To 2019

Internal neurostimulation involves a surgical implantation of electrodes at specific areas, either in the dura mater or deep inside the brain. Medical practitioners measure the invasiveness of any surgical procedure

USD 4250View Report

Europe Huntingtons Disease Therapeutics Market Report 2016

Notes:Sales, means the sales volume of Huntingtons Disease TherapeuticsRevenue, means the sales value of Huntingtons Disease TherapeuticsThis report studies sales (consumption) of Huntingtons Disease Therapeutics in Europe market, especially in

USD 3900View Report

Global Huntingtons Disease Therapeutics Sales Market Report 2016

Notes:Sales, means the sales volume of Huntingtons Disease TherapeuticsRevenue, means the sales value of Huntingtons Disease TherapeuticsThis report studies sales (consumption) of Huntingtons Disease Therapeutics in Global market, especially in

USD 4000View Report

United States Huntingtons Disease Therapeutics Market Report 2016

Notes:Sales, means the sales volume of Huntingtons Disease TherapeuticsRevenue, means the sales value of Huntingtons Disease TherapeuticsThis report studies sales (consumption) of Huntingtons Disease Therapeutics in United States market, focuses

USD 3800View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF $ 4995    $ 4995
  • Site Licence $ 9990    $ 9990
  • Enterprise Wide Licence $ 14985    $ 14985
$ 4995

Reports Details

Published Date : Feb 2016
No. of Pages :136
Country :Global
Category :Healthcare
Publisher :GBI Research
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment